GSK1016790A, a TRPV4 Agonist, Repairs Spermatogenic Dysfunction Caused By Diabetes

Area of Science:

• Reproductive Biology
• Endocrinology
• Metabolic Diseases

Background:

• Diabetic testicular damage impairs spermatogenesis and sexual function.
• Transient Receptor Potential Vanilloid 4 (TRPV4) is implicated in diabetes complications and apoptosis.
• Understanding TRPV4's role is crucial for addressing diabetic reproductive issues.

Purpose of the Study:

• To investigate the therapeutic potential of the TRPV4 agonist GSK1016790A.
• To evaluate the effects on sperm parameters, apoptosis, and testicular histopathology in diabetic mice.
• To elucidate the protective mechanisms of TRPV4 in diabetic testicular damage.

Main Methods:

• Diabetes was induced in male ICR mice using streptozotocin (STZ).
• Mice received intraperitoneal injections of GSK1016790A or saline.
• Testicular tissue and sperm parameters were analyzed after 8 weeks.

Main Results:

• STZ-induced diabetes decreased testicular TRPV4 expression, sperm count, and viability.
• Diabetic mice showed increased sperm deformity and apoptosis.
• GSK1016790A treatment reversed these negative effects by increasing TRPV4 expression.

Conclusions:

• TRPV4 activation ameliorates apoptosis in diabetic mouse testes.
• TRPV4 agonist treatment alleviates spermatogenic dysfunction caused by diabetes.
• Targeting TRPV4 may offer a novel therapeutic strategy for diabetic reproductive complications.